Trill Impact leads a 240 MSEK venture financing round in Cinclus Pharma AB, a Swedish late-stage biopharmaceutical company committed to improving the medical outcome for patients suffering from severe stomach acid-related disorders. Cinclus Pharma’s lead candidate, linaprazan glurate, is a P-CAB (potassium-competitive acid blocker) and represents a new class of anti-secretory medicines targeting patients unresponsive to existing treatment options.
Click here to read the press release
Target – Cinclus Pharma Holding AB
Buyer – Trill Impact AB
Seller – Shareholders
